English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

As our knowledge of human biology has grown, the newly found information has been leveraged to devise increasingly complicated treatments. This began with small molecule treatments that impact cell functions and has led to the rapidly maturing biologics space that largely aims to upregulate and downregulate those functions. This, in turn, has led to the emerging field of cell and gene therapy, where the aim is to create, renew, or replace cell functions and directly affect human tissue. Significant excitement has led this field to evaluate its’ benefits in a breadth of disease areas with leading candidates in oncology and congenital blood diseases. However, along with this anticipation comes questions about how the pharmaceutical industry will support these complicated and, therefore, expensive treatments to ensure patients are able to benefit from these potentially life-changing therapies.

Harmonizing Core Platforms In The Delivery of Patient-Specific Cell Therapies To Accelerate Patient Access To Life-Changing Treatments